RxDoctor Payments DataLook up a doctor →

Brent Parnell, MD

Urogynecology and Reconstructive Pelvic Surgery · Birmingham, ALNPI 1205957404

Payments from drug & device makers

$208,466in general payments, 2019–2025

Across 619 payments — averaging $336.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$79K
  • Axonics, Inc.$70K
  • Caldera Medical, Inc$31K
  • Intuitive Surgical$17K
  • Medtronic$4K
  • AbbVie$3K
  • plus $5K from 32 others

What the payments were for

  • Consulting fees$81,31039%
  • Speaking & faculty fees$82,12439%
  • Travel & lodging$15,5667%
  • Food & beverage$17,2958%
  • Education$12,1716%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Alabamato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$169,290
Medicare patients
222
Services billed
2,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron272$145,736
GemtesaVibegron215$131,777
Solifenacin Succinate386$19,299
Estradiol109$10,315
LinzessLinaclotide18$9,405
NitrofurantoinNitrofurantoin Macrocrystal260$6,378
Tolterodine Tartrate ErTolterodine Tartrate70$4,512
Methenamine Hippurate60$3,472
YuvafemEstradiol12$1,328
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst72$1,097
Trimethoprim16$695
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim96$388
Nystatin11$352
Ibuprofen81$339
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen82$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$473$145,736272 claims
Sumitomo Pharma America, Inc.Gemtesa$296$131,777215 claims
AbbVieLinzess$2,913$9,40518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Alabamaon file to place this against a meaningful peer group, so we don't.

Other urogynecology and reconstructive pelvic surgery in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →